Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mike Collins

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 18, 2020
<i>STAT3</i> Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti-PD-L1Theresa A Proia, Maneesh Singh, Richard Woessner, et al.
Blood Cancer Journal|March 16, 2025
Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutationsWarren Fiskus, Christopher P Mill, Jessica Piel, et al.
Hemasphere|January 19, 2026
Highly effective combination of BRG1/BRM inhibitor with BET inhibitor or decitabine for high-risk MECOM-rearranged AMLWarren Fiskus, Christopher P Mill, Jessica Piel, et al.
Blood|March 4, 2024
BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitorWarren Fiskus, Jessica Piel, Mike Collins, et al.
BMC Veterinary Research|June 15, 2019
Control of paratuberculosis: who, why and how. A review of 48 countriesRichard Whittington, Karsten Donat, Maarten F Weber, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 18, 2020
<i>STAT3</i> Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti-PD-L1Theresa A Proia, Maneesh Singh, Richard Woessner, et al.
Blood Cancer Journal|March 16, 2025
Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutationsWarren Fiskus, Christopher P Mill, Jessica Piel, et al.
Hemasphere|January 19, 2026
Highly effective combination of BRG1/BRM inhibitor with BET inhibitor or decitabine for high-risk MECOM-rearranged AMLWarren Fiskus, Christopher P Mill, Jessica Piel, et al.
Blood|March 4, 2024
BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitorWarren Fiskus, Jessica Piel, Mike Collins, et al.
BMC Veterinary Research|June 15, 2019
Control of paratuberculosis: who, why and how. A review of 48 countriesRichard Whittington, Karsten Donat, Maarten F Weber, et al.
Pageof 2